남미의 인슐린 투여 기기 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the South America insulin delivery devices market size was valued at USD 1.59 billion in 2025 and is estimated to grow from USD 1.70 billion in 2026 to reach USD 2.45 billion by 2031, at a CAGR of 7.5% during the forecast period (2026-2031).

South America Insulin Delivery Devices Market Trends and Insights

Rising Diabetes Burden and Insulin-Treated Population

Diabetes prevalence is creating a broad and sustained demand base for the South America insulin delivery devices market. The International Diabetes Federation reported 35.4 million adults with diabetes in South and Central America, with the total projected to reach 52 million by 2050. The same source reported that 30.4% of adults with diabetes in the region, or 10.7 million people, remained undiagnosed. Brazil had 16.6 million adults with diabetes and an age-standardized prevalence of 10.6%, providing suppliers with a large base for pens, needles, and other insulin administration products. The growing use of long-acting insulin analogs in public care supports compatible pen delivery and recurring disposable supply demand. Brazil's device registration requirements also favor suppliers with the quality documentation and approvals required for public and private distribution.

Expansion of Public Diabetes Programs and Pen Access

Public programs are shifting demand in the South American insulin delivery devices market beyond private purchasing. Brazil began a structured transition from NPH insulin to long-acting glargine across four pilot locations in February 2026, covering more than 50,000 patients in the initial phase. A Productive Development Partnership involving Biomm, Fiocruz, and Gan & Lee supported domestic glargine supply. Brazil's Ministry of Health distributed 52,350 reusable injection pens across 16 states in July 2026 as part of the national rollout. Argentina's coverage framework requires full coverage of insulin and related diabetes supplies through social insurance arrangements. Chile's Ley Ricarte Soto provides pump hardware and monthly consumables for eligible people with Type 1 diabetes, reducing cost barriers for qualifying patients.

High Out-of-Pocket Cost and Uneven Reimbursement

Household spending was a major constraint, where public coverage did not fully include advanced insulin delivery systems. In Chile, Ley Ricarte Soto covered pump hardware and recurring consumables for eligible individuals, subject to clinical criteria and administrative approval. A 2025 qualitative study identified cost, administrative complexity, and limited specialist availability outside metropolitan areas as key barriers to pump access. A 2024 systematic review reported a 64.6% treatment rate across South America, indicating that many diagnosed patients did not receive comprehensive treatment. The South American insulin delivery devices market served varied affordability segments, from basic syringes and standard pens to pumps and sensor-linked systems, while inconsistent enforcement and informal employment limited reimbursement access.

Other drivers and restraints analyzed in the detailed report include:

1. Shift From Syringes Toward Pen-Based Administration in Urban Care
2. Connected Pens, Wearable Pumps, and Continuous Glucose Monitoring Integration
3. Currency Volatility and Import Dependence

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Insulin pens held 52.44% of the South America insulin delivery devices market share in 2025, supported by their broad use in Type 2 diabetes care, public procurement, and compatibility with pen-based insulin formulations. Disposable pens continue to support public tender volumes by simplifying distribution and administration. Reusable pens are gaining traction as Brazil distributes durable hardware alongside glargine cartridges. In July 2026, Brazil's Ministry of Health distributed 52,350 reusable pens and more than 254,000 glargine cartridges across 16 states, supporting future demand for compatible needles, cartridges, patient education, and replacement supplies.

Insulin pumps are projected to grow at a CAGR of 9.35% from 2026 to 2031, making them the fastest-growing product category. Growth begins from a smaller base, as pump therapy requires clinical support, reimbursement, and a reliable supply of consumables. Patch pumps and automated hybrid closed-loop systems support growth by combining insulin administration with automated diabetes management. A real-world study of MiniMed 780G users in Argentina, Brazil, Colombia, and Chile reported that 78.1% of users achieved time-in-range targets above 70%. Syringes remain important in rural and cost-sensitive settings, while needle-free and jet injectors remain niche due to limited reimbursement support.

Non-connected devices held 71.34% of the South American insulin delivery devices market in 2025. Conventional pens, syringes, and pumps remain widely used because they are affordable and easier to include in standard procurement contracts. Public purchasers prioritize unit costs, while secondary cities often have limited digital health infrastructure and specialist support for data-driven insulin management. These factors sustain demand for conventional devices and recurring purchases of compatible consumables, even as advanced systems gain clinical acceptance.

Connected devices are projected to grow at a CAGR of 10.45% from 2026 to 2031. Bluetooth-enabled pens, sensor-linked pumps, and app-supported systems enable patients to record doses and share data with clinical teams. Argentina's revised rules and Chile's guaranteed monitoring coverage have improved access to connected care for selected patient groups. Brazil's 2026 consultation on real-time continuous glucose monitoring could create an additional public access route for connected products. Adoption will continue to depend on reimbursement, training, and consistent access to sensors and consumables.

Complete Report Scope:

• By Product Type
  • Insulin Pens
    • Reusable Pens
    • Disposable Pens
  • Insulin Pumps
    • Tethered Pumps
    • Patch / Wearable Pumps
    • Automated Hybrid Closed-Loop Systems
  • Insulin Syringes
  • Needle-Free Injectors
  • Jet Injectors
  • Others
• By Technology / Connectivity
  • Connected (Bluetooth / NFC)
  • Non-Connected / Conventional
• By Patient Age Group
  • Pediatrics (Less Than 18 yrs)
  • Adults (Equal to, More Than 18 yrs)
  • Geriatrics (Above 65 years+)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Diabetes Clinics & Centers
• By End User
  • Homecare Settings
  • Hospitals & Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
• By Geography
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

1. Abbott Laboratories
2. B. Braun Melsungen SE
3. Beckton Dickinson
4. BERLIN-CHEMIE AG
5. Biocon
6. Biomm S.A.
7. Eli Lilly and Company
8. embecta Corp.
9. Roche
10. Insulet
11. Medtronic
12. Novo Nordisk
13. Owen Mumford Limited
14. Sanofi
15. SOOIL Development Co., Ltd.
16. Tandem Diabetes Care
17. Terumo
18. Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diabetes Burden and Insulin-Treated Population
  • 4.2.2 Expansion of Public Diabetes Programs and Pen Access
  • 4.2.3 Shift From Syringes Toward Pen-Based Administration in Urban Care
  • 4.2.4 Connected Pens, Wearable Pumps, and Continuous Glucose Monitoring Integration
  • 4.2.5 Advanced-Device Demand From Specialized Type 1 Diabetes Centers
• 4.3 Market Restraints
  • 4.3.1 High Out-of-Pocket Cost and Uneven Reimbursement
  • 4.3.2 Currency Volatility and Import Dependence
  • 4.3.3 Regional Inequality in Specialist Training and Device Support
• 4.4 Value/Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Product Type
  • 5.1.1 Insulin Pens
    • 5.1.1.1 Reusable Pens
    • 5.1.1.2 Disposable Pens
  • 5.1.2 Insulin Pumps
    • 5.1.2.1 Tethered Pumps
    • 5.1.2.2 Patch / Wearable Pumps
    • 5.1.2.3 Automated Hybrid Closed-Loop Systems
  • 5.1.3 Insulin Syringes
  • 5.1.4 Needle-Free Injectors
  • 5.1.5 Jet Injectors
  • 5.1.6 Others
• 5.2 By Technology / Connectivity
  • 5.2.1 Connected (Bluetooth / NFC)
  • 5.2.2 Non-Connected / Conventional
• 5.3 By Patient Age Group
  • 5.3.1 Pediatrics (Less Than 18 yrs)
  • 5.3.2 Adults (Equal to, More Than 18 yrs)
  • 5.3.3 Geriatrics (Above 65 years+)
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
  • 5.4.4 Diabetes Clinics & Centers
• 5.5 By End User
  • 5.5.1 Homecare Settings
  • 5.5.2 Hospitals & Specialty Clinics
  • 5.5.3 Ambulatory Surgical Centers
  • 5.5.4 Others
• 5.6 By Geography
  • 5.6.1 Brazil
  • 5.6.2 Argentina
  • 5.6.3 Colombia
  • 5.6.4 Chile
  • 5.6.5 Peru
  • 5.6.6 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 B. Braun Melsungen SE
  • 6.3.3 Becton, Dickinson and Company
  • 6.3.4 BERLIN-CHEMIE AG
  • 6.3.5 Biocon Limited
  • 6.3.6 Biomm S.A.
  • 6.3.7 Eli Lilly and Company
  • 6.3.8 embecta Corp.
  • 6.3.9 F. Hoffmann-La Roche Ltd
  • 6.3.10 Insulet Corporation
  • 6.3.11 Medtronic plc
  • 6.3.12 Novo Nordisk A/S
  • 6.3.13 Owen Mumford Limited
  • 6.3.14 Sanofi S.A.
  • 6.3.15 SOOIL Development Co., Ltd.
  • 6.3.16 Tandem Diabetes Care, Inc.
  • 6.3.17 Terumo Corporation
  • 6.3.18 Ypsomed Holding AG

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment